The most expensive drug category for nonfederal hospitals in 2024 were antineoplastic targeted agents, according to a study published in the American Journal of Health-System Pharmacy.
The report, published by the American Society of Health-System Pharmacists, found that U.S. drug spending rose 10.2% in 2024 to $805.9 billion, driven largely by the increasing use of GLP-1 receptor agonists for obesity and diabetes.
Here are the top 25 therapeutic drug categories ranked by nonfederal hospital expenditure in 2024:
- Antineoplastic targeted agents: $7.3 billion
- Hemostatic modifiers: $2.99 billion
- Immunologic agents: $2.97 billion
- Biologicals: $2.9 billion
- Hospital solutions: $2.48 billion
- Antiviral drugs: $2.37 billion
- Miscellaneous: $1.9 billion
- Antiinfectives, systemic: $1.54 billion
- Diagnostic aids: $1.47 billion
- Blood factors: $1.4 billion
- Antiarthritics: $958.7 million
- Anesthetics: $949.9 million
- Respiratory therapy agents: $949.1 million
- Diabetes therapies: $844.5 million
- Gastrointestinal agents: $732.8 million
- Musculoskeletal agents: $728.1 million
- Hormones: $724.2 million
- Psychotherapeutics: $697.4 million
- Antineoplastic chemotherapies: $649 million
- Neurological disorder drugs: $564.3 million
- Cardiac agents: $509.1 million
- Vascular agents: $476.8 million
- Analgesics: $445.6 million
- Enzymes: $401.2 million
- Contraceptives: $385.3 million
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
